endogene.bio has been named a finalist in the 2026 Hello Tomorrow Challenge, one of the world's leading deep tech competitions. The company has been selected within the Medical Biotech & Pharmaceutical track, recognizing its work to generate the biological data needed to advance uterine health.
About endogene.bio
endogene.bio generates high-resolution biological data from menstrual blood, unlocking a previously inaccessible layer of human uterine biology. Our platform enables disease understanding, patient stratification, and therapeutic discovery across uterine health.
